cK-Ras antibody [234-4.2]

GeneTex

cK-Ras antibody [234-4.2]

9

For IHC-Fr: Use at a concentration of 10 microg/ml. For IHC-P: Use at a concentration of 10 microg/ml. For IP: Use at an assay dependent dilution. For WB: Use at a concentration of 5 microg/ml. Optimal dilutions/concentrations should be determined by the researcher.

ImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

234-4.2

0.1 mg/ml

Unconjugated

KRAS

KRAS proto-oncogene, GTPase

'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2, GTPase KRas, K-ras p21 protein, KRAS-ENOPH fusion, Kirsten rat sarcoma viral oncogene homolog, Kirsten rat sarcoma viral proto-oncogene, Kras-Enoph1 fusion protein, PR310 c-K-ras oncogene, c-Kirsten-ras protein, cellular c-Ki-ras2 proto-oncogene, cellular transforming proto-oncogene, oncogene KRAS2, proto-oncogene GTPase, transforming protein p21, v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog

Mouse

IgG2a

GTPase KRas

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

2°C to 8°C

12352203